Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes

Model scores of the 29,894 trials active now.

Model score 42% for any early termination, 23% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-07-20. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: metastaticchemotherapyrecurrentbreast cancerleast weeks
  Phrases that lowered it: laboratoryweeks beforeperiodaccordingsevere
• Sponsor's past termination rate: 75% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: 34.0% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 97.9% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Maximum age: 75 (lowers risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Blinding: none (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 4 (raises risk) · Sponsor's track record
• Sponsor's past trials: 4 (raises risk) · Sponsor's track record
• Disease area, dermatology: Yes (raises risk) · Disease area
• Has a data monitoring committee: No (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Cabazitaxel in Relapsed and Metastatic NSCLC NCT01852578 · started 2012 · scored riskier than 90% of active trials completed
• A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet) NCT02166658 · started 2015 · scored riskier than 99% of active trials terminated
• Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer NCT03048942 · started 2014 · scored riskier than 76% of active trials completed
• Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy. NCT02560337 · started 2015 · scored riskier than 92% of active trials completed
• Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases NCT01934894 · started 2014 · scored riskier than 72% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.